APA (7th ed.) Citation

E, E., J, A., H, B., CS, D., S, I., YK, K., . . . G, K. (2025). Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: Primary results of a multicentre, single-arm, phase 2 study. The Lancet. Oncology, 26(7), 847. https://doi.org/10.1016/S1470-2045(25)00287-6

Chicago Style (17th ed.) Citation

E, Elimova, et al. "Zanidatamab Plus Chemotherapy as First-line Treatment for Patients with HER2-positive Advanced Gastro-oesophageal Adenocarcinoma: Primary Results of a Multicentre, Single-arm, Phase 2 Study." The Lancet. Oncology 26, no. 7 (2025): 847. https://doi.org/10.1016/S1470-2045(25)00287-6.

MLA (9th ed.) Citation

E, Elimova, et al. "Zanidatamab Plus Chemotherapy as First-line Treatment for Patients with HER2-positive Advanced Gastro-oesophageal Adenocarcinoma: Primary Results of a Multicentre, Single-arm, Phase 2 Study." The Lancet. Oncology, vol. 26, no. 7, 2025, p. 847, https://doi.org/10.1016/S1470-2045(25)00287-6.